These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 28159511

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
    Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S.
    Lancet Respir Med; 2015 May; 3(5):355-66. PubMed ID: 25736990
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
    Máspero J.
    Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma.
    Carr WW, McDonald M, Meizlik P.
    Allergy Asthma Proc; 2019 Jul 01; 40(4):240-249. PubMed ID: 31262379
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
    Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P, Res-5-0010 Study Group.
    Am J Respir Crit Care Med; 2011 Nov 15; 184(10):1125-32. PubMed ID: 21852542
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea.
    Han S, Kim S, Kim H, Suh HS.
    Curr Med Res Opin; 2019 Sep 15; 35(9):1597-1605. PubMed ID: 30964365
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M.
    J Allergy Clin Immunol Pract; 2019 Jan 15; 7(1):122-130.e1. PubMed ID: 30217529
    [Abstract] [Full Text] [Related]

  • 15. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators.
    Lancet; 2016 Oct 29; 388(10056):2128-2141. PubMed ID: 27609406
    [Abstract] [Full Text] [Related]

  • 16. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
    Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P.
    Expert Opin Drug Saf; 2018 Apr 29; 17(4):429-435. PubMed ID: 29486600
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma.
    Nair P, Bardin P, Humbert M, Murphy KR, Hickey L, Garin M, Vanlandingham R, Chanez P.
    J Allergy Clin Immunol Pract; 2020 Feb 29; 8(2):555-564. PubMed ID: 31626990
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 19. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators.
    Lancet Respir Med; 2021 Mar 29; 9(3):260-274. PubMed ID: 33357499
    [Abstract] [Full Text] [Related]

  • 20. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB.
    J Allergy Clin Immunol; 2019 Jan 29; 143(1):190-200.e20. PubMed ID: 30205189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.